Eli Lilly announced Mike Mason, executive vice president and president of Lilly's diabetes and obesity division has retired. The company said in a statement that current Lilly USA president Patrik Jonsson will assume Mason's role in addition to his current responsibilities. Dr. Daniel Skovronsky is assuming the additional role of president of Lilly immunology from Jonsson while also remaining as Lilly's chief scientific officer and president of Lilly Research Laboratories.

Lilly also said vice president of corporate affairs and communications Leigh Ann Pusey has decided to leave the company, effective at the end of 2023. As Lilly rearranges executive team roles, Dr. David Hyman will become Lilly's chief medical officer and Jennifer Oleksiw will be promoted to group vice president. Dr. Mark Genovese is joining Lilly on Oct.

16 to serve as senior vice president of immunology development. He was most recently senior vice president of inflammation development at Gilead Sciences and Professor of Medicine/Immunology/Rheumatology emeritus at Stanford University.